Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SOPHiA GENETICS鈥� filings can feel like decoding the human genome itself鈥攄ense pages on machine-learning algorithms, data-privacy controls, and global regulatory paths. If you鈥檝e ever asked, 鈥淗ow do I read the SOPHiA GENETICS annual report 10-K simplified?鈥� or searched for 鈥淪OPHiA GENETICS insider trading Form 4 transactions,鈥� this page was built for you.
Stock Titan鈥檚 AI instantly converts every new document鈥攚hether a 10-Q quarterly earnings report or an 8-K material event鈥攊nto plain-English highlights. Want segment metrics on cloud-based diagnostics? Our engine flags them. Tracking 鈥淪OPHiA GENETICS executive stock transactions Form 4鈥� before a pipeline announcement? AG真人官方-time alerts mean you never miss a trade.
Here鈥檚 what you鈥檒l uncover:
- 10-K & 10-Q: Drill into R&D spend, SaaS subscription growth, and data-security disclosures with our AI-powered summaries鈥攑erfect for anyone Googling 鈥渦nderstanding SOPHiA GENETICS SEC documents with AI.鈥�
- Form 4: Live feed of 鈥淪OPHiA GENETICS Form 4 insider transactions real-time,鈥� tracking how executives manage equity tied to precision-oncology milestones.
- Proxy statements: Clarity on 鈥淪OPHiA GENETICS proxy statement executive compensation,鈥� including stock-option grants for bioinformatics talent.
- 8-K events: Immediate context when the company files 鈥淪OPHiA GENETICS 8-K material events explained,鈥� whether it鈥檚 a new hospital network partnership or regulatory approval update.
Every filing is refreshed straight from EDGAR the moment it posts. Our concise AI commentary surfaces what drives revenue, highlights key risk factors, and answers common questions like 鈥淪OPHiA GENETICS earnings report filing analysis鈥� without forcing you to wade through footnotes. Complex genomics disclosures made clear鈥攕o you can focus on decisions, not documentation.
Form 144 filed for SOPHiA GENETICS SA (SOPH) reports a proposed sale of 40,829 common shares through Morgan Stanley Smith Barney with an aggregate market value of $142,493.21, with an approximate sale date of 08/19/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 08/18/2025 and are being sold by the person identified in the filing. The filing also lists multiple prior 10b5-1 sales by the same person between 05/20/2025 and 07/23/2025, showing routine disposals of common shares under a trading plan. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for SOPHIA GENETICS SA (SOPH) discloses a proposed sale of 6,833 common shares through Morgan Stanley Smith Barney with an aggregate market value of $23,847.17. The filing lists the approximate sale date as 08/19/2025 and shows 67,579,560 shares outstanding. The shares were acquired as restricted stock units from the issuer on 08/18/2025 with payment noted on 08/18/2025. The filing also reports recent 10b5-1 sales by PHILIPPE MENU totaling 6,639 shares across several dates in May鈥揓uly 2025 with listed gross proceeds.
SOPHiA GENETICS SA prospectus supplement discloses share capital, equity incentives and corporate governance provisions relevant to debt and equity offerings. As of June 30, 2025 the company reported options and awards that could dilute equity: 495,980 shares from an Incentive Stock Option Plan (WAEP $3.18), 2,295,990 from a 2019 plan (WAEP $4.97), 11,558,048 from a 2021 Equity Incentive Plan (WAEP $5.79), 3,194,328 RSUs, 3,838,901 additional shares reserved under the 2021 plan, 400,000 warrants (exercise $4.9992) and 11,741,660 treasury shares.
The filing also describes shareholder authority and board powers, authorized conditional share capital and a capital range enabling the board to increase or decrease share capital by up to 50% within a shareholder-determined period not exceeding five years. It lists circumstances permitting issuance without pre-emptive rights, permitted offering methods, and certain exemptions and Exchange Act obligations applicable if the company ceases to qualify as a foreign private issuer.
Schedule 13G filing: On 27 June 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC jointly filed a Schedule 13G reporting a beneficial position in SOPHiA GENETICS SA (CUSIP H82027105).
The reporting persons collectively hold 3,719,140 ordinary shares, representing 5.6 % of the outstanding class. All voting and dispositive authority over the shares is shared; each entity reports zero sole voting or dispositive power and full shared power over the entire stake, triggering the 5 % disclosure threshold under Section 13(d).
ACM is organized in Delaware and operates as an investment adviser, while Braddock Partners Offshore, LP is a Cayman Islands limited partnership and Braddock Capital Offshore, LLC is a Delaware limited-liability company. The certification states that the securities were acquired 鈥榥ot for the purpose of or with the effect of changing or influencing the control鈥� of the issuer. No additional group members, subsidiary acquisitions, or 5 %-or-less disclaimers are indicated. An Exhibit A Joint Filing Agreement accompanies the submission.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
